Related Experiment Video
Updated: May 18, 2026
10:39
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
Targeting interleukins to treat severe asthma
David Gibeon1, Andrew N Menzies-Gow
1Royal Brompton Hospital, London, UK.
Expert Review of Respiratory Medicine
|September 14, 2012
Summary
Severe asthma is a complex condition with various inflammatory pathways. Research into interleukins (cytokines) offers promising new therapeutic targets for refractory asthma patients, with ongoing clinical trials showing potential.
Area of Science:
- Immunology
- Pulmonology
- Pharmacology
Background:
- Severe asthma is a heterogeneous disease with distinct phenotypes.
- Refractory disease in severe asthma leads to increased morbidity and mortality.
- Current therapies for severe asthma remain limited, necessitating novel treatment strategies.
Purpose of the Study:
- To explore the role of interleukins in severe asthma pathogenesis.
- To identify interleukins as potential therapeutic targets for severe asthma.
- To review the current status of interleukin-targeted therapies in clinical development.
Main Methods:
- Review of current literature on asthma pathophysiology and immunology.
- Analysis of the role of interleukins (cytokines) in inflammatory processes.
- Examination of ongoing clinical trials involving monoclonal antibodies targeting interleukins.
Main Results:
- Interleukins are key cell-signaling cytokines driving inflammatory changes in asthma.
- Understanding interleukin pathways has improved insights into asthma pathogenesis.
- Monoclonal antibody therapies targeting specific interleukins show promise in early-phase clinical trials.
Conclusions:
- Interleukin pathways represent a significant area for novel therapeutic development in severe asthma.
- Targeting specific interleukins with monoclonal antibodies offers a promising avenue for treating refractory asthma.
- Further clinical investigation is warranted to translate these findings into effective treatments for severe asthma patients.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: